30.01
0.15 (0.50%)
| Penutupan Terdahulu | 29.86 |
| Buka | 29.86 |
| Jumlah Dagangan | 1,151,597 |
| Purata Dagangan (3B) | 1,264,075 |
| Modal Pasaran | 1,676,916,480 |
| Harga / Jualan (P/S) | 6.57 |
| Harga / Buku (P/B) | 5.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -36.20% |
| Margin Operasi (TTM) | -39.67% |
| EPS Cair (TTM) | -1.69 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 55.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.02% |
| Nisbah Semasa (MRQ) | 8.95 |
| Aliran Tunai Operasi (OCF TTM) | -83.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -58.77 M |
| Pulangan Atas Aset (ROA TTM) | -13.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | PROCEPT BioRobotics Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.75 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.22% |
| % Dimiliki oleh Institusi | 93.06% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 51.00 (Morgan Stanley, 69.94%) | Beli |
| 51.00 (Wells Fargo, 69.94%) | Beli | |
| Median | 50.00 (66.61%) | |
| Rendah | 50.00 (Piper Sandler, 66.61%) | Beli |
| 50.00 (TD Cowen, 66.61%) | Beli | |
| 50.00 (Truist Securities, 66.61%) | Beli | |
| Purata | 50.40 (67.94%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 31.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 51.00 (69.94%) | Beli | 29.53 |
| Piper Sandler | 05 Nov 2025 | 50.00 (66.61%) | Beli | 31.61 |
| TD Cowen | 05 Nov 2025 | 50.00 (66.61%) | Beli | 31.61 |
| Wells Fargo | 05 Nov 2025 | 51.00 (69.94%) | Beli | 31.61 |
| Truist Securities | 15 Oct 2025 | 50.00 (66.61%) | Beli | 33.76 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 |
| 04 Nov 2025 | Pengumuman | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance |
| 15 Oct 2025 | Pengumuman | PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |